Please note that the recruitment of patients to VIABLE clinical trial was successfully completed.

OK

View the Map

Participating Medical Centers

You have entered website for VIABLE study – phase III global clinical trial for prostate cancer treatment (DCVAC/PCa). This clinical trial is intended for patients with metastatic castration- resistant prostate cancer, who meet the entry criteria and consent to participate.

Only a physician conducting a clinical evaluation of an investigational treatment DCVAC/PCa can decide whether or not a patient can be included in a clinical trial. This is based on the criteria defined in the study protocol which is approved by the health care authorities.

The term “investigational treatment” means that it has not yet been approved by the European Medicines Agency (EMA) or Food and Drug Administration (FDA) for the treatment of prostate cancer.

You can find the participating medical centres listed below.

Sweden

Participating Medical Center Address Principal investigator Phone  
Universitetssjukhuset Örebro,
Onkologiska Kliniken
Södra Grev Rosengatan, M-huset vån 5,
70185 Örebro
Dr. Johan Ahlgren (+46) 703 952314 E-mail
Cancer Centrum
Norrlands Universitetssjukhus,
901 85 UMEÅ
Dr. Camilla Thellenberg-Karlsson E-mail